{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:12:17Z","timestamp":1794852737337,"version":"4.9.1"},"reference-count":79,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T00:00:00Z","timestamp":1522195200000},"content-version":"vor","delay-in-days":392,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","onlinejacc.org","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.jacc.2016.10.018","type":"journal-article","created":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T12:15:12Z","timestamp":1478261712000},"page":"1617-1636","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients"],"prefix":"10.1016","volume":"69","author":[{"given":"Donald M.","family":"Lloyd-Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Huffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal N.","family":"Karmali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshak M.","family":"Sanghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet S.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Pelser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick A.","family":"Masoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"David C.","family":"Goff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2016.10.018_bib1","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/CIR.0000000000000350","article-title":"Heart disease and stroke statistics\u20142016 update: a report from the American Heart Association [published correction appears in Circulation. 2016;133:e599]","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.10.018_bib2","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1161\/CIR.0b013e3182285a81","article-title":"Value of primordial and\u00a0primary prevention for cardiovascular disease: a policy statement from the American Heart Association","volume":"124","author":"Weintraub","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.10.018_bib3","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1056\/NEJMp1110421","article-title":"The \u201cMillion Hearts\u201d initiative\u2014preventing heart attacks and strokes","volume":"365","author":"Frieden","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.10.018_bib4","unstructured":"Million Hearts website. Available at: http:\/\/millionhearts.hhs.gov\/. Accessed August 1,\u00a02016."},{"key":"10.1016\/j.jacc.2016.10.018_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2015.6681","article-title":"Paying for prevention: a novel test of Medicare value-based payment for cardiovascular risk reduction","volume":"314","author":"Sanghavi","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2016.10.018_bib6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/jamacardio.2016.0218","article-title":"Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews","volume":"1","author":"Karmali","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2016.10.018_bib7","first-page":"144","article-title":"Prevalence of hypertension and controlled hypertension\u2014United States, 2007\u20132010","volume":"62","author":"Gillespie","year":"2013","journal-title":"MMWR Morb Mortal Weekly Rep"},{"key":"10.1016\/j.jacc.2016.10.018_bib8","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.15585\/mmwr.mm6447a1","article-title":"Prevalence of cholesterol treatment eligibility and medication use among adults\u2014United States, 2005\u20132012","volume":"64","author":"Mercado","year":"2015","journal-title":"MMWR Morbid Mortal Weekly Rep"},{"key":"10.1016\/j.jacc.2016.10.018_bib9","doi-asserted-by":"crossref","first-page":"396","DOI":"10.7326\/0003-4819-150-6-200903170-00008","article-title":"Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement","volume":"150","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2016.10.018_bib10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-150-6-200903170-00009","article-title":"Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force","volume":"150","author":"Wolff","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2016.10.018_bib11","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement","volume":"164","author":"Bibbins-Domingo","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2016.10.018_bib12","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0140-6736(00)03307-9","article-title":"Effects of\u00a0ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials","volume":"356","author":"Neal","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.10.018_bib13","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0140-6736(14)62070-5","article-title":"Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data","volume":"384","author":"Sundstr\u00f6m","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.10.018_bib14","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A\u00a0randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.10.018_bib15","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1600175","article-title":"Blood-pressure lowering in intermediate-risk persons without cardiovascular disease","volume":"374","author":"Lonn","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.10.018_bib16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.7326\/M14-0773","article-title":"Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis","volume":"162","author":"Sundstrom","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2016.10.018_bib17","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14\u00a0randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.10.018_bib18","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy\u00a0and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.10.018_bib19","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.10.018_bib20","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ejhf.247","article-title":"Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF","volume":"17","author":"Feinstein","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2016.10.018_bib21","first-page":"CD009329","article-title":"Pharmacological interventions for smoking cessation: an overview and network meta-analysis","author":"Cahill","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"25 Pt B","key":"10.1016\/j.jacc.2016.10.018_bib22","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.10.018_bib23","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1161\/CIRCOUTCOMES.113.000112","article-title":"Trends in vascular risk factor treatment and control in US stroke survivors: the National Health and Nutrition Examination Surveys (1999-2010)","volume":"6","author":"Shah","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2016.10.018_bib24","doi-asserted-by":"crossref","first-page":"e001709","DOI":"10.1161\/JAHA.114.001709","article-title":"Trends in myocardial infarction secondary prevention: the National Health and Nutrition Examination Surveys (NHANES), 1999-2012","volume":"4","author":"Shah","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2016.10.018_bib25","first-page":"957","article-title":"Matching the intensity of risk factor management with the hazard for coronary disease events. September 14-15, 1995","volume":"27","year":"1996","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.10.018_bib26","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in\u00a0Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.10.018_bib27","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"issue":"25 Pt B","key":"10.1016\/j.jacc.2016.10.018_bib28","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines [published correction appears in J Am Coll Cardiol. 2014;63(25 Pt B):3026]","volume":"63","author":"Goff","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.10.018_bib29","doi-asserted-by":"crossref","first-page":"627","DOI":"10.7326\/0003-4819-154-9-201105030-00008","article-title":"Individualized guidelines: the potential for increasing quality and reducing costs","volume":"154","author":"Eddy","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2016.10.018_bib30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.7326\/0003-4819-152-2-201001190-00004","article-title":"Optimizing statin treatment for primary prevention of coronary artery disease","volume":"152","author":"Hayward","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2016.10.018_bib31","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1161\/CIRCULATIONAHA.113.002290","article-title":"Using benefit-based tailored treatment to improve the use of antihypertensive medications","volume":"128","author":"Sussman","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.10.018_bib32","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1016\/j.jacc.2015.09.089","article-title":"Primary prevention with statins: ACC\/AHA risk-based approach versus trial-based approaches to guide statin therapy","volume":"66","author":"Mortensen","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.10.018_bib33","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1161\/CIRCULATIONAHA.115.018383","article-title":"Individualized statin benefit for determining statin eligibility in the\u00a0primary prevention of cardiovascular disease","volume":"133","author":"Thanassoulis","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.10.018_bib34","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1001\/jamainternmed.2014.5336","article-title":"Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the Women's Health Study","volume":"174","author":"Cook","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2016.10.018_bib35","doi-asserted-by":"crossref","first-page":"266","DOI":"10.7326\/M14-1281","article-title":"An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort","volume":"162","author":"DeFilippis","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2016.10.018_bib36","unstructured":"DeFilippis AP, Young R, McEvoy JW, et al. Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort [published online ahead of print July 19, 2016]. Eur Heart J. Available at: http:\/\/dx.doi.org\/10.1093\/eurheartj\/ehw301. http:\/\/eurheartj.oxfordjournals.org\/content\/early\/2016\/07\/18\/eurheartj.ehw301.long. Accessed August 1,\u00a02016."},{"key":"10.1016\/j.jacc.2016.10.018_bib37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/jamacardio.2016.4494","article-title":"Assessing and refining myocardial infarction risk estimation among patients with human immunodeficiency virus: a study by the Centers for AIDS Research Network of Integrated Clinical Systems","volume":"2","author":"Feinstein","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2016.10.018_bib38","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jama.2014.2630","article-title":"Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations","volume":"311","author":"Muntner","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2016.10.018_bib39","doi-asserted-by":"crossref","first-page":"e005991","DOI":"10.1136\/bmjopen-2014-005991","article-title":"Real-life evaluation of European and American high-risk strategies for primary prevention of cardiovascular disease in patients with first myocardial infarction","volume":"4","author":"Mortensen","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacc.2016.10.018_bib40","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jacc.2014.05.056","article-title":"Accuracy of statin assignment using the 2013 AHA\/ACC cholesterol guideline versus the 2001 NCEP ATP III guideline: correlation with atherosclerotic plaque imaging","volume":"64","author":"Johnson","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.10.018_bib41","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/jama.2015.7515","article-title":"Guideline-based statin eligibility, coronary artery calcification, and cardiovascular events","volume":"314","author":"Pursnani","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2016.10.018_bib42","doi-asserted-by":"crossref","first-page":"e003410","DOI":"10.1161\/JAHA.116.003410","article-title":"2013 ACC\/AHA cholesterol guideline versus 2004 NCEP ATP III guideline in the prediction of coronary artery calcification progression in a Korean population","volume":"5","author":"Cho","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2016.10.018_bib43","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1161\/CIRCOUTCOMES.114.001139","article-title":"Atherosclerotic cardiovascular disease prevention: a comparison between the Third Adult Treatment Panel and the new 2013 treatment of blood cholesterol guidelines","volume":"7","author":"Paixao","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2016.10.018_bib44","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/jama.2015.6822","article-title":"Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease","volume":"314","author":"Pandya","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2016.10.018_bib45","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJMoa1315665","article-title":"Application of new cholesterol guidelines to a population-based sample","volume":"370","author":"Pencina","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.10.018_bib46","doi-asserted-by":"crossref","first-page":"e003558","DOI":"10.1161\/JAHA.116.003558","article-title":"2013 ACC\/AHA cholesterol guideline and implications for Healthy People 2020 cardiovascular disease prevention goals","volume":"5","author":"Egan","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2016.10.018_bib47","doi-asserted-by":"crossref","first-page":"e002275","DOI":"10.1161\/JAHA.115.002275","article-title":"Can antihypertensive treatment restore the risk of cardiovascular disease to ideal levels? The Coronary Artery Risk Development in Young Adults (CARDIA) Study and the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"4","author":"Liu","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2016.10.018_bib48","unstructured":"QIntervention 2014. Available at: http:\/\/qintervention.org. Accessed August 1,\u00a02016."},{"key":"10.1016\/j.jacc.2016.10.018_bib49","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"Gaede","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.10.018_bib50","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.10.018_bib51","doi-asserted-by":"crossref","first-page":"a1655","DOI":"10.1136\/bmj.a1655","article-title":"Developing and evaluating complex interventions: the new Medical Research Council guidance","volume":"337","author":"Craig","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2016.10.018_bib52","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/eurheartj\/ehl403","article-title":"Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial","volume":"27","author":"Sever","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2016.10.018_bib53","first-page":"CD009868","article-title":"Fixed-dose combination therapy for the prevention of cardiovascular disease","author":"de Cates","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2016.10.018_bib54","series-title":"Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. (Updated March 2011)","year":"2011"},{"key":"10.1016\/j.jacc.2016.10.018_bib55","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"Lloyd-Jones","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.10.018_bib56","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2288-7-10","article-title":"Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews","volume":"7","author":"Shea","year":"2007","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jacc.2016.10.018_bib57","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2016.10.018_bib58","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.yrtph.2012.06.009","article-title":"Using the negative exponential distribution to quantitatively review the evidence on how rapidly the excess risk of ischaemic heart disease declines following quitting smoking","volume":"64","author":"Lee","year":"2012","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.jacc.2016.10.018_bib59","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.yrtph.2013.11.013","article-title":"Estimating the decline in excess risk of cerebrovascular disease following quitting smoking\u2014a systematic review based on the negative exponential model","volume":"68","author":"Lee","year":"2014","journal-title":"Regul Toxicol Pharmacol"},{"issue":"suppl 2","key":"10.1016\/j.jacc.2016.10.018_bib60","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1161\/01.cir.0000437740.48606.d1","volume":"129","author":"Eckel","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.10.018_bib61","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1161\/01.CIR.0000146378.65439.7A","article-title":"Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria","volume":"110","author":"Asselbergs","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.10.018_bib62","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.10.018_bib63","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1161\/01.CIR.103.13.1721","article-title":"Low-dose metoprolol CR\/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS)","volume":"103","author":"Hedblad","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.10.018_bib64","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.STR.0000147041.00840.59","article-title":"Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS\u2014a randomized double-blind trial","volume":"35","author":"Zanchetti","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2016.10.018_bib65","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa1200303","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet","volume":"368","author":"Estruch","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.10.018_bib66","series-title":"2008 Physical Activity Guidelines for Americans","year":"2008"},{"issue":"suppl 2","key":"10.1016\/j.jacc.2016.10.018_bib67","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1161\/01.cir.0000437739.71477.ee","volume":"129","author":"Jensen","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.10.018_bib68","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1161\/CIRCULATIONAHA.109.192703","article-title":"Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond","volume":"121","author":"Lloyd-Jones","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.10.018_bib69","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCOUTCOMES.109.869727","article-title":"Distribution of 10-year and lifetime predicted risks for cardiovascular disease in US adults: findings from the National Health and Nutrition Examination Survey 2003 to 2006","volume":"3","author":"Marma","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2016.10.018_bib70","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.111.035733","article-title":"Status of cardiovascular health in US adults: prevalence estimates from the National Health and Nutrition Examination Surveys (NHANES) 2003-2008","volume":"125","author":"Shay","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.10.018_bib71","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/ije\/dyr117","article-title":"Epidemiology, epigenetics and the \u2018Gloomy Prospect\u2019: embracing randomness in population health research and practice","volume":"40","author":"Smith","year":"2011","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jacc.2016.10.018_bib72","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.10.018_bib73","doi-asserted-by":"crossref","first-page":"e1001293","DOI":"10.1371\/journal.pmed.1001293","article-title":"Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis","volume":"9","author":"Lv","year":"2012","journal-title":"PLoS Med"},{"key":"10.1016\/j.jacc.2016.10.018_bib74","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1097\/HJH.0000000000000380","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk\u2014overview and meta-analyses of randomized trials","volume":"32","author":"Thomopoulos","year":"2014","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.jacc.2016.10.018_bib75","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/HJH.0000000000000378","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials","volume":"32","author":"Thomopoulos","year":"2014","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.jacc.2016.10.018_bib76","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/HJH.0000000000000881","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials","volume":"34","author":"Thomopoulos","year":"2016","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.jacc.2016.10.018_bib77","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0140-6736(15)00805-3","article-title":"Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis","volume":"387","author":"Xie","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.10.018_bib78","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.amjcard.2006.09.099","article-title":"Risk factor burden in middle age and lifetime risks for cardiovascular and non-cardiovascular death (Chicago Heart Association Detection Project in Industry)","volume":"99","author":"Lloyd-Jones","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2016.10.018_bib79","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1161\/CIRCULATIONAHA.105.548206","article-title":"Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age","volume":"113","author":"Lloyd-Jones","year":"2006","journal-title":"Circulation"}],"updated-by":[{"DOI":"10.1016\/j.jacc.2017.02.015","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T00:00:00Z","timestamp":1490659200000}}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510971636692X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510971636692X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T04:51:08Z","timestamp":1568523068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073510971636692X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":79,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S073510971636692X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2016.10.018","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jacc.2017.02.015","asserted-by":"object"}]},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2016.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Heart Association, Inc., and the American College of Cardiology Foundation","name":"copyright","label":"Copyright"}]}}